Fingerstick

Harvard Wyss Institute’s eRapid multiplexed biosensor technology licensed to StataDX to enable new diagnostics for neurological, cardiovascular, and renal diseases

Retrieved on: 
Monday, June 27, 2022
Diagnosis, OTD, Patient, Ageing, Research, Biofouling, GLOBE, COVID-19, Wyss Institute for Biologically Inspired Engineering, Blood, Industry, Hormone, Heart failure, Neurology, Sport, Commonwealth, Degenerative disease, Therapy, Efficiency, NFL, Wyss Institute, Population, Bioinspiration, DARPA, Diabetes, RNA, Chronic kidney disease, Fluid mechanics, Time, CEO, Protein, Conditional sentence, Harvard Medical School, Kidney, Multiple sclerosis, Harvard University, Wyss, Harvard John A. Paulson School of Engineering and Applied Sciences, Hospital, Technology, Fingerstick, Gaps, Institute, Biomarker, Applied science, Ingber, Antibody, CTO, Pharmacy, Pharmaceutical industry, Medical imaging, Management, Medical device, Engineering

Wyss Institute for Biologically Inspired Engineering at Havard University, June 27, 2022 (GLOBE NEWSWIRE) -- (BOSTON) Today the Wyss Institute for Biologically Inspired Engineering at Harvard University and Cambridge-based StataDX Inc. announce that the Wyss Institutes affinity-based, multiplexed, electrochemical sensing technology, eRapid , has been licensed to the startup.

Key Points: 
  • Wyss Institute for Biologically Inspired Engineering at Havard University, June 27, 2022 (GLOBE NEWSWIRE) -- (BOSTON) Today the Wyss Institute for Biologically Inspired Engineering at Harvard University and Cambridge-based StataDX Inc. announce that the Wyss Institutes affinity-based, multiplexed, electrochemical sensing technology, eRapid , has been licensed to the startup.
  • The license, coordinated by Harvards Office of Technology Development (OTD), grants StataDX exclusive worldwide access to the eRapid technology in the fields of neurological, cardiovascular, and renal diseases.
  • These ultimately could result in life-changing and life-saving outcomes for patients with a vast range of diseases.
  • Biofouling poses a pervasive challenge to the development of electrochemistry-based diagnostics, which could be used to solve important diagnostic problems.

Imec signs licensing agreement with miDiagnostics to commercialize its patented technology for fast and reliable COVID-19 diagnosis based on exhaled breath

Retrieved on: 
Thursday, October 14, 2021
View, Exhaled breath condensate, Digital technology, International, Technology, History, Aerosol, Blood, Saliva, Diagnosis, Industry, Cancer, Silicon, Flemish Government, Knowledge, Education, Infection, Multimedia, Johns Hopkins University, Artificial intelligence, RNA, Health, Public health, PCR, Investment, Company, Fingerstick, CEO, Brussels Airport, Entrepreneurship, Nanofluidic circuitry, Research, ICT, COVID-19, Pharmaceutical industry

"I note with great pride that we have run an impressive course in the past months," says Luc Van den hove, CEO at imec.

Key Points: 
  • "I note with great pride that we have run an impressive course in the past months," says Luc Van den hove, CEO at imec.
  • "We have succeeded in transforming a promising concept and groundbreaking technology into a functional proof-of-concept that has passed both user tests and clinical studies.
  • This is the first time that we have gone this far in the development of our chip technology towards commercialization.
  • The license agreement with miDiagnostics is an important milestone for imec: Our breakthrough technology will help curb the COVID-19 pandemic in the foreseeable future."

Global WholeHealth Partners, Corp. (OTC: GWHP) Confirms Their Antibody Test Kit Detects Fast Spreading Mutated COVID-19 Strains, UK (B.1.1.7) and South Africa (B.1.351)

Retrieved on: 
Thursday, February 11, 2021
Fingerstick

Global WholeHealth Partners recognizes that there is a crucial need for faster testing and faster results when it comes to fighting the COVID.

Key Points: 
  • Global WholeHealth Partners recognizes that there is a crucial need for faster testing and faster results when it comes to fighting the COVID.
  • Global WholeHealth Partners knows that the quicker the test results can be reviewed by a Front-Line Healthcare Worker, the quicker we can stop the spread of this disease.
  • With the new fingerstick test, healthcare providers can prick a patients finger and get results in minutes without having to wait for venous blood.
  • Global WholeHealth Partners will be able to distribute these tests to more urgent cares, hospitals, and to help curb the spread of CoViD19 SARS2.

Global WholeHealth Partners Corp. (GWHP) Announces It Now Offers the New FDA Cleared Fingerstick for Rapid COVID-19 Test Results in Minutes

Retrieved on: 
Thursday, November 5, 2020
Infectious diseases, Medical specialties, Medicine, Tropical diseases, Zoonoses, Vaccine-preventable diseases, Medical terminology, Medical tests, Ebola, Rapid diagnostic test, Malaria, Fingerstick

With the new fingerstick test, healthcare providers can prick a patients finger and get results in minutes without having to wait for venous blood.

Key Points: 
  • With the new fingerstick test, healthcare providers can prick a patients finger and get results in minutes without having to wait for venous blood.
  • On September 23, 2020, that EUA was being reissued to authorize the test for POC use using fingerstick blood samples.
  • 2260-11-2019, are tests like Rapid Ebola, Rapid Dengue Fever Antibody and Antigen, Rapid Tuberculosis (TB), Rapid Malaria, and many other rapid tests.
  • 2260-11-2019, are tests like Rapid Ebola, Rapid Dengue Fever Antibody and Antigen, Rapid Tuberculosis (TB), Rapid Malaria, and many other rapid tests.

Inflammatix Announces $7.4 Million in Additional BARDA Funding to Advance ViraBac EZ Acute Infection Test

Retrieved on: 
Thursday, October 29, 2020
Health, Infectious diseases, Genetics, General Health, Pharmaceutical, Biotechnology, Articles, Health sciences, Branches of biology, Pharmaceuticals policy, Veterinary medicine, Evolutionary biology, Biomedical Advanced Research and Development Authority, Antimicrobial resistance, Antibiotic, Etest, Fingerstick

The contract is part of a BARDA contract worth up to $72 million, if all options are exercised.

Key Points: 
  • The contract is part of a BARDA contract worth up to $72 million, if all options are exercised.
  • The test will use a fingerstick collection and capillary blood sample, and is designed for use in primary care, urgent care and other outpatient clinical settings.
  • Increasing and incorrect antibiotic use leads to antibiotic-resistant bacteria that become more difficult and costly to treat, and more deadly.
  • We are pleased to continue to partner with BARDA in the development of our ViraBac EZ test and Myrna instrument.

rHEALTH's FVIII Point-of-Care Device Awarded $1.5M Direct-to-Phase II Grant from the NIH

Retrieved on: 
Thursday, October 8, 2020
Blood tests, Fingerstick, Medicine

The award is to rHEALTH's affiliate, the DNA Medicine Institute (DMI), which has granted rHEALTH commercial rights to the technology.

Key Points: 
  • The award is to rHEALTH's affiliate, the DNA Medicine Institute (DMI), which has granted rHEALTH commercial rights to the technology.
  • The focus of the grant is to further develop the company's fingerstick-based point-of-care technology for monitoring both FVIII and emicizumab.
  • Conventional central lab FVIII testing require large machines and is difficult to perform.
  • They will work with rHEALTH to plan field-based studies of the device in the developing world.

Sight Diagnostics Raises $71M To Accelerate Global Expansion of its FDA 510(k) Cleared, CE Marked Finger-prick Blood Analyzer

Retrieved on: 
Wednesday, August 5, 2020
Science, Biotechnology, Research, Pharmaceutical, Health, Medical devices, Technology, Other Technology, Blood tests, Complete blood count, Olo, Fingerstick, Olo, Blood cell, Medical test, Health

Founded in 2011, Sight Diagnostics aims to transform blood testing through its flagship Sight OLO analyzer which automates the identification and quantification of different blood cell types and anomalies.

Key Points: 
  • Founded in 2011, Sight Diagnostics aims to transform blood testing through its flagship Sight OLO analyzer which automates the identification and quantification of different blood cell types and anomalies.
  • Sight OLO delivers lab-grade CBC results by measuring 19 different blood parameters in minutes from either a fingerstick or a venous sample.
  • Founded in 2011, Sight Diagnostics aims to transform health systems and patient outcomes through accurate and pain-free blood diagnostic testing.
  • Sights latest blood analyzer, Sight OLO, performs a Complete Blood Count, the most commonly ordered blood test, in minutes.

Blood Collection Device Manufacturer Boston Microfluidics Appoints Linh Hoang, MD, PhD as CEO

Retrieved on: 
Tuesday, June 9, 2020
Medical specialties, Blood tests, Branches of biology, Hematology, Medicine, Blood, Transfusion medicine, Biotechnology, Microfluidics, Fingerstick, Venous blood, Venipuncture

"Laboratory diagnostics inform a majority of medical decisions, and now more than ever, blood collection must evolve to enable at-home solutions.

Key Points: 
  • "Laboratory diagnostics inform a majority of medical decisions, and now more than ever, blood collection must evolve to enable at-home solutions.
  • Options such as BMF's collection device (in development) enables at-home collection which is a critical piece to ramping up serology testing.
  • The study demonstrates equivalency in analytical performance between venous blood draw and finger prick blood collection, which is enabled by the BMF's device.
  • Boston Microfluidics develops simple, intuitive, and needle-free blood collection devices designed to greatly simplify and revolutionize blood testing globally.

XaTek's ClotChip Earns FDA's Breakthrough Device Designation

Retrieved on: 
Tuesday, March 3, 2020
Blood tests, Branches of biology, Medicine, Transfusion medicine, Diabetes, Medical specialties, Glucose meter, Fingerstick, Bleeding, Blood sugar level, Bluetooth

CLEVELAND, March 3, 2020 /PRNewswire/ --XaTek Inc. today announced that the company has received Breakthrough Device designation from the U.S. Food and Drug Administration (FDA) for its in-development ClotChip, marking a significant and distinguishing step in advancing the company's life-changing portable blood-clotting sensor toward commercialization.

Key Points: 
  • CLEVELAND, March 3, 2020 /PRNewswire/ --XaTek Inc. today announced that the company has received Breakthrough Device designation from the U.S. Food and Drug Administration (FDA) for its in-development ClotChip, marking a significant and distinguishing step in advancing the company's life-changing portable blood-clotting sensor toward commercialization.
  • ClotChip measures a patient's bleeding risk profile at bedside from a single drop of blood obtained from a fingerstick, much like a glucometer measures a patient's blood-glucose level.
  • ClotChip is a handheld fully portable device enabled for WiFi and Bluetooth.
  • The device utilizes technology conceived nearly 10 years ago by electrical engineers at Case Western Reserve University.

rHEALTH Technology Granted US Patent for Small Volume Blood Handling in Point-of-Care Devices

Retrieved on: 
Thursday, January 9, 2020
Chemistry, Physical sciences, Natural sciences, Blood tests, Laboratory techniques, Hematology, Venipuncture, Assay, Sampling, Metallurgical assay, Fingerstick

The patent describes a system for collection and delivery of minute blood samples to provide dramatic simplification of clinical diagnoses.

Key Points: 
  • The patent describes a system for collection and delivery of minute blood samples to provide dramatic simplification of clinical diagnoses.
  • One of the major bottlenecks in point-of-care diagnostics is the handling of tiny blood samples from a fingerstick.
  • The linchpin in blood analysis is accurate blood collection, sampling, and manipulation of minute blood volumes.
  • With this latest issuance, the rHEALTH technology has a dozen issued patents that cover sample handling, small blood volume analysis, massive assay multiplexing, and device design.